Other: Blood collection
( DrugBank: - / KEGG DRUG: - )
7 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 15 | Inclusion body myositis | 1 |
| 28 | Systemic amyloidosis | 1 |
| 36 | Epidermolysis bullosa | 1 |
| 49 | Systemic lupus erythematosus | 2 |
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 66 | IgA nephropathy | 1 |
| 67 | Polycystic kidney disease | 1 |
| 223 | Primary membranoproliferative glomerulonephritis | 1 |
15. Inclusion body myositis
Clinical trials : 49 / Drugs : 73 - (DrugBank : 19) / Drug target genes : 14 - Drug target pathways : 134
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
28. Systemic amyloidosis
Clinical trials : 454 / Drugs : 430 - (DrugBank : 90) / Drug target genes : 66 - Drug target pathways : 183
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
36. Epidermolysis bullosa
Clinical trials : 197 / Drugs : 223 - (DrugBank : 46) / Drug target genes : 53 - Drug target pathways : 136
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
49. Systemic lupus erythematosus
Clinical trials : 1,414 / Drugs : 1,077 - (DrugBank : 181) / Drug target genes : 130 - Drug target pathways : 209
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
66. IgA nephropathy
Clinical trials : 407 / Drugs : 342 - (DrugBank : 73) / Drug target genes : 40 - Drug target pathways : 146
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
67. Polycystic kidney disease
Clinical trials : 251 / Drugs : 278 - (DrugBank : 69) / Drug target genes : 97 - Drug target pathways : 182
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
223. Primary membranoproliferative glomerulonephritis
Clinical trials : 243 / Drugs : 296 - (DrugBank : 84) / Drug target genes : 46 - Drug target pathways : 169
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|